|Bid||47.29 x 100|
|Ask||47.30 x 300|
|Day's Range||46.28 - 47.84|
|52 Week Range||23.60 - 63.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||56.91|
NEW YORK, NY / ACCESSWIRE / April 13, 2018 / U.S. markets jumped Thursday as investor's attention shifted from current geopolitical tensions to the upcoming earnings season. Bank stocks were the top gainers ...
NEW YORK, NY / ACCESSWIRE / April 10, 2018 / U.S. markets rallied in early trading Monday on the strength of technology stocks and the easing of trade relations between the U.S. and China. However, most ...
MADISON, Wis., April 9, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company plans to release its first-quarter 2018 financial results after the close of the U.S. financial markets on April 26, 2018. Following the release, company management will host a webcast and conference call at 5 p.m. EDT to discuss financial results and business progress.
Stock Monitor: Biocept Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free earnings report on Exact Sciences Corp. (NASDAQ: EXAS ) ("EXAS"). ...
Axogen and Exact Sciences have been big winners in the healthcare sector as they've launched new and attractive products into big addressable markets. Many investors overlooked these opportunities because ...
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / The S&P 500 and the Nasdaq posted their worst daily loss since February 8th on Monday as a sharp decline in Facebook shares triggered a selloff in the technology ...
Exact Sciences' campaign featuring the entertainer and his wife isn't what the market expected.
MADISON, Wis., March 20, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS), the company that developed and commercialized Cologuard®, the only FDA-approved, noninvasive stool DNA-based test for early detection of colorectal cancer, today announced that Mark Stenhouse has been appointed to the new role of president, Cologuard. Stenhouse, vice president, U.S. Immunology at AbbVie, will assume this new position on April 2, 2018. "More than 85 million people are eligible to be screened with Cologuard, and Mark brings the experience and passion to help us reach further into this enormous population," said Kevin Conroy, chairman and CEO of Exact Sciences.
MADISON, Wis., March 19, 2018 /PRNewswire/ -- Grammy and Emmy award winner, and Tony award nominee, the multi-talented musician, singer and actor Harry Connick, Jr. and his wife of 24 years and former model, Jill Connick, recently marked the fifth anniversary of Jill's recovery from breast cancer. As Jill credits timely screening and early detection for being a cancer survivor today, she is joining Harry to share their experience and to raise awareness of another cancer for which timely screening is critical: colon cancer.* Their efforts will support The New 50, a public education campaign sponsored by Exact Sciences, that debuts today during Colorectal Cancer Awareness Month. "I know firsthand the value of early detection," said Connick.
NEW YORK, March 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
MADISON, Wis., March 6, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that Paul J. Limburg, M.D., M.P.H., has been appointed the company's co-chief medical officer. Dr. Limburg is a gastroenterologist and a professor of medicine at Mayo Clinic. "We are delighted to welcome Dr. Limburg and believe he'll play a critical leadership role in our mission to eradicate colon cancer," said Kevin T. Conroy, chairman and CEO of Exact Sciences.
TUCSON, Ariz., March 1, 2018 /PRNewswire/ -- Three-time PGA TOUR Champions winner Jerry Kelly is raising the bar on his competitors when it comes to colon cancer screening. At a players-only meeting before the Cologuard Classic today, Kelly urged his friends and competitors to get screened for colon cancer. Throughout the season, Kelly will be asking PGA TOUR Champions pros to take the Cologuard Challenge, a pledge which asks them to talk to their health care provider and get screened for colon cancer.
MADISON, Wis., March 1, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences during March and invited investors to participate by webcast. The webcasts can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer.
TUCSON, Ariz., Feb. 28, 2018 /PRNewswire/ -- The PGA TOUR Champions professionals playing in this week's tournament haven't officially teed off yet, but the Cologuard Classic is already giving back. At today's Pro-Am event, representatives from the Tucson Conquistadores and Cologuard presented a $50,000 check to the Vince Lombardi Cancer Foundation to help raise colon cancer awareness and support the fight against cancer. Assisting in the check presentation was MVP quarterback Aaron Rodgers, a participant in Wednesday's Pro-Am event and friend of Cologuard Classic ambassador and PGA TOUR Champions player, Jerry Kelly.
NEW YORK, NY / ACCESSWIRE / February 28, 2018 / U.S. markets dropped for the first time in four sessions on Tuesday as comments made by new Federal Reserve Chairman Jerome Powell hinted interest rates ...
What: Exact Sciences Corp., a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer, will open the Nasdaq Stock Market remotely from the Cologuard ...
"Colorectal cancer screening rates are stubbornly low, leaving millions of Americans unscreened for the No. 2 cancer killer," said Kevin Conroy, chairman and CEO of Exact Sciences. "Cologuard was designed to help more people get screened and it is doing just that.
Exact Sciences plunged to a six-month low Friday after first-quarter guidance was dinged by the severe flu season.
571,000 people were screened with Cologuard during 2017 - Fourth quarter revenue increased 148 percent to $87.4 million - Gross margin increased 1,250 basis points to 73 percent during the fourth quarter ...
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Exact Sciences Corporation (NASDAQ: EXAS ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018, at 5:00 PM ...
Exact Sciences (EXAS) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.